MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction

Jesper Jensen1,6*, Morten Schou1,6, Caroline Kistorp2,6, Jens Faber3,6, Tine W. Hansen4, Magnus T. Jensen5, Henrik U. Andersen4, Peter Rossing4,6, Tina Vilsbøll4,6 and Peter G. Jørgensen1

Abstract

Background: Mid-regional pro-atrial natriuretic peptide (MR-proANP) is a useful biomarker in outpatients with type 2 diabetes (T2D) to diagnose heart failure (HF). Elevated B-type natriuretic peptides are included in the definition of HF with preserved ejection fraction (HFpEF) but little is known about the prognostic value of including A-type natriuretic peptides (MR-proANP) in the evaluation of patients with T2D.

Methods: We prospectively evaluated the risk of incident cardiovascular (CV) events in outpatients with T2D (n = 806, mean ± standard deviation age 64 ± 10 years, 65% male, median [interquartile range] duration of diabetes 12 [6–17] years, 17.5% with symptomatic HFpEF) according to MR-proANP levels and stratified according to HF-status including further stratification according to a prespecified cut-off level of MR-proANP.

Results: A total of 126 CV events occurred (median follow-up 4.8 [4.1–5.3] years). An elevated MR-proANP, with a cut-off of 60 pmol/l or as a continuous variable, was associated with incident CV events (p < 0.001). Compared to patients without HF, patients with HFpEF and high MR-proANP (≥ 60 pmol/l; median 124 [89–202] pmol/l) and patients with HF and reduced ejection fraction (HFrEF) had a higher risk of CV events (multivariable model; hazard ratio (HR) 2.56 [95% CI 1.64–4.00] and 3.32 [1.64–6.74], respectively). Conversely, patients with HFpEF and low MR-proANP (< 60 pmol/l; median 46 [32–56] pmol/l) did not have an increased risk (HR 2.18 [0.78–6.14]).

Conclusions: Patients with T2D and HFpEF with high MR-proANP levels had an increased risk for CV events compared to patients with HFpEF without elevated MR-proANP and compared to patients without HF, supporting the use of MR-proANP in the definition of HFpEF from a prognostic point-of-view.

Keywords: Cardiovascular disease, Diabetes complications, Macrovascular disease, Type 2 diabetes, MR-proANP, Heart failure
of Cardiology (ESC), the diagnosis of HFpEF includes signs and/or symptoms of HF, echocardiographic criteria, and increased natriuretic peptides [4]. Natriuretic peptides are sensitive markers of hemodynamic status and elevated levels might represent an unstable state of HFpEF, that is, a maladapted cardiac remodelling leading to subsequent cardiovascular (CV) events [5]. However, only B-type natriuretic peptides (B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP)) are included in the HFpEF diagnosis and data on A-type natriuretic peptides (mid-regional pro-atrial natriuretic peptide (MR-proANP)) are lacking [6]. In a recent position paper from the ESC HF association, measurement of natriuretic peptides in high-risk populations such as patients with T2D was recommended, but again, evidence is primarily existing on B-type natriuretic peptides, and more data on A-type natriuretic peptides are needed [7]. A-type natriuretic peptides could carry similar relevant prognostic information when included in the HFpEF definition, as has previously been shown for B-type natriuretic peptides [4]. In the acute setting, MR-proANP has shown to improve the diagnostic performance of B-type natriuretic peptides for HF in obese patients [8]. Also, MR-proANP has been shown to be associated with clinical outcomes in HFpEF, not HF with reduced ejection fraction (HFrEF), [9] and in an at-risk community population, NT-proBNP and MR-proANP have shown to predict incident HF [10]. Moreover, MR-proANP levels have shown similar diagnostic performance as NT-proBNP in primary care patients suspected of non-acute HF [11]. And in a high-risk population such as outpatients with T2D, our group recently reported, that MR-proANP with a cut-off of less than 60 pmol/l was efficient to rule out HFrEF and at this cut-off, the highest ability to similarly rule out HFpEF was obtained. However, the accuracy to rule out HFpEF was still relatively low. Despite having a relatively low diagnostic value in HFpEF, the prognostic value of MR-proANP in HFpEF could potentially guide the diabetologist in identifying patients with a high risk of future clinical events, in which further cardiac work up should be performed and relevant treatment started [2]. In the present study, we sought to evaluate the prognostic value of MR-proANP and examine the significance of HFpEF in the presence and absence of elevated MR-proANP levels using the pre-specified cut-off level.

Methods
The study was conducted in accordance with the Helsinki Declaration and approved by the Danish National Committee on Biomedical Research Ethics (amendment to protocol no. H-3-2009-139) [12].

Study population
The study population consisted of patients with T2D from the Thousand&2 Study, which has previously been described in detail [13]. In brief, patients followed at two specialized diabetes clinics in Denmark, the Center for Diabetes research (CfD) at Herlev-Gentofte University Hospital and the Steno Diabetes Center Copenhagen (SDCC), were eligible to participate [13]. A total of 1030 patients were included in the Thousand&2 Study (participation rate 47.8%). Of these, two hundred and twenty-four patients with either prior heart valve replacement, atrial fibrillation and/or missing laboratory values/echocardiographic measurements were excluded rendering 806 patients available for the present study [2].

Baseline study visit, biochemistry and echocardiograms
The baseline study visit, biochemistry and echocardiograms have previously been described in detail [2, 14]. In brief, all study related data were collected at or in close conjunction with the baseline study visit including blood samples for the study biobank and the echocardiographic assessments. After immediate centrifugation, blood samples were stored at −80 °C and MR-proANP was analyzed in a single batch in July 2017 using the KRYPTOR assay (BRAHMS GmbH/Thermo Fisher Scientific, Hennigsdorf, Germany) [2]. Echocardiograms were primarily (>95%) performed and analyzed by a single investigator (P.G.J.) in accordance with the existing European and American guidelines as previously described [14, 15]. Albuminuria was defined as urine albumin/creatinine ratio above 30 mg/g or urine albumin above 30 mg/day on at least 2 consecutive measurements [13].

Heart failure definitions
Based on the current European and American guidelines we defined HF as follows: HFpEF was defined as self-reported dyspnea corresponding to the New York Heart Association (NYHA) functional class II–IV and presence of at least one of the following echocardiographic findings (a–d): (a) left ventricular ejection fraction (LVEF) >40% and ≤50%, (b) ratio of early diastolic mitral inflow velocity (E) to early diastolic septal annular velocity (e′) (E/e′ septal) ≥15, (c) increased left ventricular (LV) mass index (>95 g/cm² for women and >115 g/cm² for men), and (d) left atrial volume index >34 mL/m². HFrEF was defined as a LVEF ≤40%, regardless of reported dyspnea. The definitions were specified before the MR-proANP analyses were performed.

Follow-up
Information on incident CV events were retrieved through national registries. A CV event was defined as
the composite of admission with CV disease (including HF, coronary revascularization, myocardial infarction, cardiac arrest, cerebrovascular disease and peripheral artery disease) and CV death.

Statistics
Baseline characteristics for all four groups were compared using a one-way analysis of variance for continuous variables and, in case of non-normal distribution, Mann–Whitney U tests or Kruskall-Wallis tests were used. Categorical variables were compared using the Chi-square test. MR-proANP levels were non-normally distributed and, therefore, log2-transformed before continuous analyses. Cumulative incidence curves with non-CV death as competing risk for incident CV events according to HF status were performed, and for HFpEF also according to the prespecified dichotomized MR-proANP level of 60 pmol/l. Moreover, a cumulative incidence curve for incident CV events according to the dichotomized MR-proANP level was performed with non-CV death as competing risk. Poisson regression with restricted cubic splines was used to examine the association of incidence rates and MR-proANP levels. The Akaike information criterion was used to determine the optimal number of knots. A multivariable Cox proportional hazards model was constructed including the prespecified variables age, sex, duration of diabetes, known CV disease, uncontrolled systolic blood pressure (SBP) above 170 mmHg, body mass index (BMI) and albuminuria. The performance of the multivariable model was assessed by C-statistics and continuous net reclassification index (NRI) with and without HF or MR-proANP in the model. Associations between MR-proANP levels and the echocardiographic measures were analyzed. A p-value less than 0.05 (two-sided) was considered significant. Statistics were calculated using R for Mac, version 3.4.2 (R Project for Statistical Computing, Vienna University of Economics and Business administration, Austria).

Results
Baseline characteristics
Baseline characteristics for the 806 included patients are presented in Table 1. Compared to patients with HFpEF and a low MR-proANP, patients with HFpEF and a high MR-proANP were characterized by being older, with a higher frequency of males, a higher prevalence of known ischemic heart disease, a higher creatinine level and were to a higher extent treated with betablockers, diuretics and anti-platelet therapy. Generally, patients with HFpEF and a high MR-proANP were similar to patients with HFrEF. During a median [interquartile range (IQR)] follow-up of 4.8 [4.1–5.3] years, a total of 126 incident CV events occurred in the total cohort.

Incidences of CV events according to HF status
Patients with HFrEF, followed by patients with HFpEF and a high MR-proANP level, had the highest incidence of CV events (Fig. 1). Notably, patients with HFpEF and a low MR-proANP had an incidence of CV events, which was not statistically different to the incidence in patients without HF (Fig. 1). MR-proANP levels were associated with incident CV events; both analyzed as a dichotomized and a continuous variable (Fig. 2). In the univariable analysis and in the multivariable model, a higher MR-proANP level was associated with a higher risk of an incident CV event, with a hazard ratio (HR) [95% confidence interval (CI)] of 2.09 [1.73–2.52] and 1.71 [1.34–2.18] per doubling of MR-proANP, p < 0.001, respectively (Fig. 3). Patients with HFpEF and a low MR-proANP did not have a significantly different risk for an incident CV event compared to patients without HF (univariable analysis; HR 1.30 [0.48–3.56], multivariable model; HR 2.18 [0.78–6.14], p > 0.05) (Fig. 3). In contrast, the risk was significantly increased in both patients with HFpEF and high MR-proANP (univariable analysis; HR 3.47 [2.34–5.13], multivariable model; HR 2.56 [1.64–4.00], p < 0.001) and in patients with HFpEF (univariable analysis; HR 6.25 [3.23–12.11], multivariable model; HR 3.32 [1.64–6.74], p < 0.001) (Fig. 3). A sensitivity analysis with adjustment for SBP as a continuous variable instead of adjustment for SBP > 170 mmHg and with further adjustment for estimated glomerular filtration rate (eGFR) in addition to the prespecified variables showed overall similar results. Similarly, a sensitivity with adjustment for HbA1c instead of duration of type 2 diabetes in the prespecified model, also showed overall similar results (data not shown). In a competing risks regression model with the prespecified variables, sub-hazard ratios showed similar results as the traditional hazard ratios (Additional file 1: Table S1).

Model performance
Results of the prognostic performance of models with MR-proANP and HF status alone and added to the multivariable adjusted model are shown Table 2. An MR-proANP level with a cut-off of 60 pmol/l had only limited prognostic performance assessed by c-statistics, 0.57 (0.54–0.62). MR-proANP as a continuous variable had a c-statistic of 0.66 (0.61–0.71), which was lower than the multivariable adjusted model alone, 0.72 (0.68–0.78). Adding MR-proANP as a continuous variable to the multivariable model, resulted in a significant
increase in NRI of 27.1% [7.6–46.6], \( p = 0.007 \), and adding HF status showed an NRI of 32.8% [13.5–52.0], \( p < 0.001 \).

### Associations between MR-proANP levels and echocardiographic measures

As supplemental analyses, the associations between MR-proANP levels and the echocardiographic measures were analyzed in univariable and multivariable

---

**Table 1 Baseline characteristics according to heart failure status**

|                      | No HF   | HfPEF low MR-proANP | HfPEF high MR-proANP | HFrEF   | p-value |
|----------------------|---------|---------------------|----------------------|----------|---------|
| n                    | 646     | 27                  | 114                  | 19       |         |
| Age, year (median [IQR]) | 64.4 [56.9–69.8] | 60.2 [53.0–65.7] | 69.8 [64.7–74.9] | 72.2 [64.9–76.6] | <0.001 |
| Male, n (%)          | 433 (67.0) | 10 (37.0)          | 67 (58.8)            | 15 (78.9) | 0.003   |
| Body mass index, kg/m² (median [IQR]) | 28.7 [26.0–32.8] | 31.8 [28.9–38.2] | 31.6 [28.0–34.2] | 28.4 [26.0–31.3] | <0.001 |
| T2DM duration, year (median [IQR]) | 11.0 [5.0–16.0] | 15.0 [8.0–23.5] | 15.0 [7.3–20.8] | 12.0 [10.0–23.0] | <0.001 |
| Known ischemic heart disease, n (%) | 97 (15.0) | 2 (7.4)            | 42 (36.8)            | 9 (47.4)  | <0.001  |
| Smoking, n (%)       |         |                     |                      |          |         |
| Never                | 276 (42.7) | 13 (48.1)           | 47 (41.2)            | 8 (42.1)  |         |
| Active               | 88 (13.6) | 5 (18.5)            | 19 (16.7)            | 2 (10.5)  |         |
| Former               | 282 (43.7) | 9 (33.3)            | 48 (42.1)            | 9 (47.4)  |         |
| Systolic blood pressure, mmHg (mean (sd)) | 134.6 (16.2) | 134.8 (15.7) | 139.1 (20.0) | 141.3 (18.6) | 0.029   |
| Diastolic blood pressure, mmHg (mean (sd)) | 80.0 (10.8) | 79.8 (10.1) | 77.8 (10.9) | 81.6 (9.3)  | 0.226   |
| Heart rate, bpm (mean (sd)) | 72.4 (11.2) | 76.6 (9.7) | 68.2 (10.8) | 72.7 (11.6) | <0.001  |
| Angina, n (%)        | 44 (7.0) | 6 (22.2)            | 23 (20.7)            | 4 (22.2)  | <0.001  |
| Dyspnea, n (%)       | 162 (25.1) | 27 (100)            | 114 (100)            | 8 (42.1)  | <0.001  |
| New York Heart Association class, n (%) |         |                     |                      |          |         |
| I                    | 484 (74.9) | 0 (0.0)             | 0 (0.0)              | 11 (57.9) |         |
| II                   | 117 (18.1) | 13 (48.1)           | 66 (57.9)            | 5 (26.3)  |         |
| III                  | 38 (5.9) | 14 (51.9)           | 43 (37.7)            | 3 (15.8)  |         |
| IV                   | 7 (1.1) | 0 (0.0)             | 5 (4.4)              | 0 (0.0)   |         |
| MR-proANP, pmol/l (median [IQR]) | 65 [42–99] | 46 [32–56] | 124 [89–202] | 125 [94–209] | <0.001 |
| LDL cholesterol, mmol/l (median [IQR]) | 2.0 [1.5–2.6] | 2.1 [1.8–2.6] | 1.9 [1.6–2.3] | 2.1 [1.8–2.9] | 0.468   |
| Creatinine, μmol/l (median [IQR]) | 77.0 [65.0–93.0] | 69.5 [60.3–76.8] | 97.0 [77.0–123.0] | 78.0 [66.5–96.0] | <0.001 |
| Albuminuria, n (%)   | 153 (23.7) | 5 (18.5)            | 37 (32.5)            | 6 (31.6)  | 0.077   |
| HbA1C, mmol/mol (median [IQR]) | 55.0 [48.0–65.0] | 55.0 [48.5–71.0] | 54.0 [48.0–67.0] | 53.0 [44.5–69.0] | 0.777   |
| Hemoglobin, mmol/L (mean (SD)) | 8.7 (0.9) | 8.4 (0.8) | 8.1 (1.0) | 8.8 (0.9) | <0.001 |
| Treatment with       |         |                     |                      |          |         |
| Metformin, n (%)     | 488 (75.5) | 17 (63.0)           | 64 (56.1)            | 11 (57.9) | <0.001  |
| Dipeptidyl peptide-4 inhibitor, n (%) | 69 (10.7) | 4 (14.8) | 9 (7.9) | 1 (5.3) | 0.586 |
| Sulfonylurea, n (%)  | 106 (16.4) | 2 (7.4)             | 16 (14.0)            | 5 (26.3)  | 0.335   |
| Glucagon-like peptide-1 receptor agonist, n (%) | 155 (24.0) | 7 (25.9) | 18 (15.8) | 3 (15.8) | 0.222    |
| Insulin, n (%)       | 275 (42.6) | 17 (63.0)           | 68 (59.6)            | 13 (68.4) | <0.001  |
| Beta-blocker, n (%)  | 129 (20.0) | 5 (18.5)            | 54 (47.4)            | 10 (52.6) | <0.001  |
| ACE inhibitor, n (%) | 256 (39.6) | 6 (22.2)            | 37 (32.5)            | 10 (52.6) | 0.081   |
| Angiotensin-II receptor blocker, n (%) | 241 (37.3) | 10 (37.0) | 56 (49.1) | 7 (36.8) | 0.123 |
| Calcium channel blocker, n (%) | 200 (31.0) | 10 (37.0) | 44 (38.6) | 5 (26.3) | 0.364 |
| Diuretics*, n (%)    | 297 (46.0) | 7 (25.9)            | 77 (67.5)            | 11 (57.9) | <0.001  |
| Statins, n (%)       | 508 (78.6) | 22 (81.5)           | 88 (77.2)            | 12 (63.2) | 0.419   |
| Anti-platelet therapy, n (%) | 423 (65.5) | 16 (59.3) | 90 (78.9) | 15 (78.9) | 0.019   |

For patients with HfPEF, stratification according to low (<60 pmol/l) or high MR-proANP level is presented. p-value for comparison of all four groups

ACE, angiotensin converting enzyme; bpm, beats per minute; HbA1c, glycated hemoglobin; HfPEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; IQR, interquartile range; LDL, low density lipoprotein; mm Hg, millimeters of mercury; MR-proANP, mid-regional pro-atrial natriuretic peptide; sd, standard deviation; T2D, type 2 diabetes mellitus

* Include loop diuretics, thiazides, or mineralocorticoid receptor antagonists
analyses (Additional file 1: Table S2). In the multivariable analyses, MR-proANP was significantly associated with left ventricular mass index, left atrial volume index, the E/A ratio, the E/e' mean ratio, and with measures of left ventricular systolic function.

Discussion
In this large cohort of patients with T2D in an outpatient, non-acute setting, we found that; (1) higher MR-proANP levels were highly associated with incident CV events; (2) MR-proANP levels effectively stratified patients with symptomatic HFpEF and predicted the outcome of incident CV events during almost five years of follow-up; (3) patients with symptomatic HFpEF and high MR-proANP had an increased risk of CV events compared to patients with HFpEF without elevated MR-proANP and compared to patients without HF; (4) adding MR-proANP as a continuous variable or adding HF status to a model with clinical risk markers significantly reclassified 27.1% and 32.8% respectively, but only resulted in limited improvements in C-statistics; (5) finally, MR-proANP was associated with key echocardiographic measures of both diastolic—including left atrial volume index—and systolic function.

In patients with HF, natriuretic peptides are established diagnostic and prognostic biomarkers, and also carry relevant prognostic information in other cardiovascular diseases [7, 16]. Natriuretic peptides act as a surrogate measure of the underlying left ventricular dysfunction in HF [17]. The ventricular dysfunction causes volume expansion and/or pressure overload, leading to increased stress in the atrial and ventricular walls and thereby an increased release of natriuretic peptides. Moreover, natriuretic peptides have also been associated with metabolic changes potentially modulating their property as prognostic markers beyond the indication of ventricular dysfunction [18]. In some series of patients with HF (22% with concomitant T2D), the more
recently developed biomarker MR-proANP has outperformed the extensively studied biomarker NT-proBNP in the prediction of mortality, [19] and some data indicate that MR-proANP may be more sensitive and specific than NT-proBNP in diagnosing HFpEF [20]. In patients with T2D, the most common co-existing conditions that cause HF is coronary artery disease and hypertension, [21] and MR-proANP has previously been shown to be independently associated with CV mortality in both primary and secondary care patients with T2D [22, 23]. In 1100 outpatients with T2D prospectively followed in primary care in the Netherlands, MR-proANP as a continuous variable was independently associated with both CV and all-cause mortality during a follow-up of 10 years with adjusted HRs of 2.42 [1.74–3.38] and 2.23 [1.78–2.79], respectively, in a multivariable model adjusted for age, sex, smoking, BMI, SBP, duration of diabetes, serum creatinine level, cholesterol-to-high-density lipoprotein ratio, macrovascular complications, albuminuria, and the use of lipid-lowering and anti-hypertensive medications [23]. Similarly, in a prospective cohort of more than 700 outpatients with T2D in secondary care in Austria, a one standard deviation increase in MR-proANP was associated with a 1.85-fold [1.49–2.30] increase in the risk of the composite outcome of unplanned hospitalization for CV disease or death during a median follow-up of 15 months, in a multivariable model adjusted for NYHA functional class, age, serum creatinine level, low-density lipoprotein level, level of serum triglycerides, hemoglobin A1c, SBP and BMI [22]. In addition to key differences compared with the present study in characteristics of the cohorts, follow-up times and definitions of outcome, no stratification according to HF status based on echocardiography was performed in these previous studies.
Stratification according to HF status enables the opportunity to link the MR-proANP levels to the underlying changes in cardiac structure seen in HF patients. In outpatients with T2D, HFrEF is infrequent and can be ruled out with a low MR-proANP level, [2] which is important as therapies have been shown to reduce both morbidity and mortality in patients with HFrEF irrespective of concomitant T2D [4]. Conversely, HfPEF is frequent in outpatients with T2D, [2] and it has been hypothesized that T2D-related processes can cause HfPEF by direct effects on cardiac structure, [24, 25] and these changes in cardiac structure have been shown to be associated with CV events and all-cause mortality [5]. In a recent study, in which 37% had concomitant T2D, MR-proANP was associated with clinical outcomes in HfPEF, not in HFrEF, supporting the use of MR-proANP as a prognostic marker in patients with HfPEF [9]. Also, the use of MR-proANP in patients with HfPEF is supported by the current data, with a strong association between MR-proANP levels and key echocardiographic measures of diastolic—including left atrial volume index—and systolic function which are impaired in these patients. Based on the prognostic data in this large cohort of outpatients with T2D, an MR-proANP level of 60 pmol/l can support the diabetologist in identifying patients with HfPEF and increased risk of CV events, thus acting as a guide to identify patients for further cardiac diagnostic work up; patients with dyspnea and an MR-proANP of 60 pmol/l or greater should be referred for an echocardiogram. At present, the identification of patients with HfPEF has no therapeutic consequence as no effective therapies exist, [26] but patients with HfPEF and increased risk of CV events are candidates for ongoing clinical trials.

The used definition of HfPEF in the present study was prespecified based on the current knowledge in the field. However, as no definitive consensus on the definition of HFpEF exists across guidelines and for inclusion in clinical trials, other definitions could have been valid, and this should be kept in mind when comparing the present results with other studies on HfPEF. Strengths of the present study include the comprehensive characterization of the patients at baseline including echocardiographic assessment. The MR-proANP levels were analyzed in a single batch, consequently reducing potential analytical variability, using a contemporary assay. As the aim was to specifically generate data on MR-proANP, no conclusions regarding potential differences to B-type natriuretic peptides can be made from the present data. The completeness of the registered CV events in the Danish national registries diminishes the possible misclassification of events. Conclusions regarding differences in outcomes between the groups are limited due to the low number of patients in the group with HfPEF and low MR-proANP and in the group with HFrEF, and larger studies are needed to investigate these possible differences. Additionally, the findings of this study should be tested in other cohorts to ascertain their robustness. The results of the present study cannot be extrapolated to non-diabetic patients or to patients with T2D and atrial fibrillation. Extrapolation to other races than Caucasians should be done with caution. Moreover, despite adjustments for clinically important confounders in the multivariable analyses, the risk of other factors confounding the results is still possible and should be kept in mind when interpreting the results of the present study. A strict cost–benefit analysis should be performed before implementation of routine MR-proANP measurements in the clinical setting.

Conclusions
In conclusion, our study demonstrates that MR-proANP levels were highly associated with incident cardiovascular events in outpatients with type 2 diabetes and that patients with HfPEF and high MR-proANP levels had a higher risk for cardiovascular events compared to patients with HfPEF without elevated MR-proANP and compared to patients without heart failure. The present findings support the use of MR-proANP as a test in outpatients with type 2 diabetes and support the inclusion of MR-proANP in the definition of HfPEF from a prognostic point-of-view.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12933-020-01155-9.

Abbreviations
ANP: A-type natriuretic peptide; BMI: Body mass index; BNP: B-type natriuretic peptide; CED: Center for Diabetes research, Herlev-Gentofte University Hospital; CI: Confidence interval; CV: Cardiovascular; E: Early diastolic mitral inflow velocity; e′ septal: Early diastolic septal annular velocity; eGFR: Estimated glomerular filtration rate; ESC: European society of cardiology; HF: Heart failure; HFrEF: Heart failure with preserved ejection fraction; HfPEF: Heart failure with reduced ejection fraction; HR: Hazard ratio; IQR: Interquartile range; LVID: Left ventricular diameter; LVPW: Left ventricular posterior wall thickness; MR-proANP: Mid-regional pro-atrial natriuretic peptide; NRI: Net reclassification index; NT-ANP: N-terminal ANP; NT-proBNP: N-terminal pro-B type natriuretic peptide; NYHA: New York Heart Association; SBP: Systolic blood pressure; sd: Standard deviation; SDCC: Steno Diabetes Center Copenhagen; T2D: Type 2 diabetes.

Acknowledgements
Not applicable.

Authors’ contributions
JJ designed and performed data analysis and wrote the first draft of the manuscript. PGJ designed and performed data collection, designed and performed
data analysis. MS designed data analysis. MTJ performed data collection. All authors revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

**Funding**
Thermo Fisher Scientific (Germany) funded the MR-proANP kits. The sponsor had no influence on design of the study, collection, analysis or interpretation of the data, manuscript preparation or on the decision to submit the manuscript for publication.

**Availability of data and materials**
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**
All participants provided written informed consent and the study was approved by the Danish National Committee on Biomedical Research Ethics (amendment to protocol no. H-3-2009-139).

**Consent for publication**
Not applicable.

**Competing interests**
M.S. reports lecture fees received from Novo Nordisk and Boehringer Ingelheim. M.T.J. has served as consultant, on advisory boards, or invited speaker for AstraZeneca, Novo Nordisk, Novartis, and General Electric. H.U.A. owns stocks in Novo Nordisk. HUA is on advisory boards for Novo Nordisk, Abbott and AstraZeneca and has received a lecture fee from Nordic Infucare. P.R. reports grants from and shares in Novo Nordisk, service on advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, Eli Lilly, Merck, Mundipharma, Astellas, Sanofi Aventis (all fees to his institution) and receipt of lecture fees from Bayer, AstraZeneca and Eli Lilly (to his institution). T.V. reports grants/personal fees/unrestricted research grants from Novo Nordisk, Boehringer, Sanofi, Eli Lilly, MSD/Merck, BMIS, Sun Pharmaceuticals, Mundipharma and Amgen. P.G.J. reports lecture fees from Novo Nordisk and AstraZeneca. The authors have no other relevant conflicts of interest.

**Author details**
1 Department of Cardiology, Herlev and Gentofte Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark. 2 Department of Endocrinology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark. 3 Department of Endocrinology, Herlev and Gentofte Hospital, Blegdamsvej 9, 2100 Copenhagen, Denmark. 4 Steno Diabetes Center Copenhagen, Niels Steensens Vej 2, 2820 Gentofte, Denmark. 5 Department of Cardiology, Copenhagen University Hospital Amager-Hvidovre Hospital, Kettegård Alle 30, 2650 Hvidovre, Denmark. 6 Faculty of Health and Medical Sciences, Copenhagen University, Blegdamsvej 38, 2200 Copenhagen, Denmark.

**Received: 9 July 2020 Accepted: 10 October 2020**

**Published online: 16 October 2020**

**References**
1. Bell DSH, Goncalves E. Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose-lowering medications. Diabetes Obes Metab. 2019;21:1277–90.
2. Jensen J, Schou M, Kistorp C, Faber J, Hansen TW, Jensen MT, et al. Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes. Diabetes Obes Metab. 2019;21:736–40.
3. Zakri R, Cowie MR. Heart failure with preserved ejection fraction: controversies, challenges and future directions. Heart. 2018;104:377–84.
4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.
5. Jorgensen PS, Schou M, Biering-Sorensen T, Mogelvang R, Fritz-Hansen T, Vilsboll T, et al. An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes. Int J Cardiol. 2019;289:119–24.
6. Tanase DM, Radu S, Al Shurabj S, Baroi GL, Florida Costea C, Turluc MD, et al. Natriuretic peptides in heart failure with preserved left ventricular ejection fraction: from molecular evidences to clinical implications. Int J Mol Sci. 2019;20:2629.
7. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozuharov N, et al. Heart failure association of the European Society of Cardiology: practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21:715–31.
8. Miasel A, Mueller C, Nowak R, Peacock WF, Landsberg JW, Ponikowski P, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;55:2062–76.
9. Putho BN, Savu A, Kaul P, Ezekowitz J, Dyck JR, Anderson TJ, et al. Left atrial remodelling, mid-regional pro-atrial natriuretic peptide, and prognosis across a range of ejection fractions in heart failure. Eur Heart J Cardiovasc Imag. 2020.
10. Smith JC, Newton-Cheh C, Almgren P, Strick J, Morgenstalher NG, Bergmann A, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;56:1712–9.
11. Gohar A, Rutten FH, den Ruiter H, Kelder JC, van Haehling S, Anker SD, et al. Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure. Eur J Heart Fail. 2019;21:1219–27.
12. Jensen MT, Sogaard P, Anderssen HU, Bech J, Hansen TF, Galatius S, et al. Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study. Diabetologia. 2014;57:672–80.
13. Jorgensen PG, Jensen MT, Mogelvang R, van Scholten BJ, Bech J, Fritz-Hansen T, et al. Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics. Diab Vasc Dis Res. 2016;13:321–30.
14. Jorgensen PG, Jensen MT, Mogelvang R, Fritz-Hansen T, Galatius S, Biering-Sorensen T, et al. Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function. Int J Cardiol. 2016;221:114–21.
15. Jorgensen PG, Biering-Sorensen T, Mogelvang R, Fritz-Hansen T, Vilsboll T, Rossing P, et al. Predictive value of echocardiography in Type 2 diabetes. Eur Heart J Cardiovasc Imaging. 2019;20:687–93.
16. Wong YK, Cheung CYY, Tang CS, Hai JSH, Lee CH, Lau KK, et al. High-sensitivity troponin I and B-type natriuretic peptide biomarkers for prediction of cardiovascular events in patients with coronary artery disease with and without diabetes mellitus. Cardiovasc Diabetol. 2019;18:171.
17. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Heid IM, Maders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertension in the population. J Hypertens. 2000;18:1121–8.
18. Musauch A, Pitzner M, Bals M, Budde K, Kastenmuller G, Zylla S, et al. Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP Cardiovasc Diabetol. 2018;17:120.
19. Moertl O, Berger R, Struck J, Gleiss A, Hammer A, Morgenstalher NG, et al. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death. J Am Coll Cardiol. 2009;53:1783–90.
20. Cui K, Huang W, Fan J, Lei H. Midregional pro-atrial natriuretic peptide is a superior biomarker to N-terminal pro-B-type natriuretic peptide in the diagnosis of heart failure patients with preserved ejection fraction. Medicine. 2018;97:e12277.
21. Seferovic PM, Potere MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the heart failure association of the European Society of Cardiology. Eur J Heart Fail. 2018;20:20853–72.
22. Maier C, Clodi M, Neuhold S, Resl M, Elhenicky M, Prager R, et al. Endothelial markers may link kidney function to cardiovascular events in type 2 diabetes. Diabetes Care. 2009;32:1800–5.
23. van Hateren KJ, Landman GW, Klevstra N, Groenier KH, Struck J, Navis GJ, et al. The midregional fragment of pro-A-type natriuretic peptide, blood pressure, and mortality in a prospective cohort study of patients with type 2 diabetes (ZODIAC-25). Diabetes Care. 2013;36:1347–52.
24. Seferovic PM, Paulus WJ. Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. Eur Heart J. 2015;36(17);27a–27c.

25. Jensen MT, Fung K, Aung N, Sanghvi MM, Chadalavada S, Paiva JM, et al. Changes in cardiac morphology and function in individuals with diabetes mellitus: The UK biobank cardiovascular magnetic resonance substudy. Circ Cardiovasc Imaging. 2019;12:e009476.

26. Lam CSP, Voors AA, de Boer RA, Solomon SD, van Veldhuisen DJ. Heart failure with preserved ejection fraction: from mechanisms to therapies. Eur Heart J. 2018;39;2780–92.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.